This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vrijens, B Articles by Goetghebeur, E Search for Related Content PubMed PubMed Citation Articles by Vrijens, B Articles by Goetghebeur, E Social Bookmarking                         What's this?

The impact of compliance in pharmacokinetic studies

Department of Applied Mathematics and Informatics, University of Ghent, Belgium

E Goetghebeur

Department of Applied Mathematics and Informatics, University of Ghent, Belgium, Els.Goetghebeur{at}rug.ac.be

In population pharmacokinetic (PK) studies, one observes just a few concentration measures spread out in time, on a sizable sample of the target population. Common-sense dictates that for estimation of a drug exposure-plasma concentration relationship, one needs accurate information on drug intake history besides the concentration measures. The population PK literature is well aware of this. Studies of simulated compliance behaviour have helped quantify the problem with naive compliance estimators and pointed towards a solution. In this paper we look at actually observed compliance patterns recorded via electronic monitoring. We simulate a documented pharmacokinetic model from the hypertensive literature on top of these and come to some interesting findings. In this clinical trial the problem of noncompliance is much more dramatic than simulated compliance patterns suggested so far. The systematic errors made by compliance naive estimators can be corrected when using timing explicit hierarchical nonlinear models and accurate information on a number of previous dose timings. When it is possible to observe irregular drug intake times in a well-controlled study, a substantial amount of precision is retrieved from the same number of data points. In general, the estimators of PK parameters benefit greatly from information that enters through greater variation in the drug-exposure process. Here we find support for the claim that noncompliance as a rich natural experiment of dosing variation can be a blessing rather than a curse from the information/learning point of view.

Statistical Methods in Medical Research, Vol. 8, No. 3, 247-262 (1999)
DOI: 10.1177/096228029900800305


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Jin, B. G. Pollock, E. Frank, J. Florian, M. Kirshner, A. Fagiolini, D. J. Kupfer, M. R. Gastonguay, G. Kepple, Y. Feng, et al. The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram J. Clin. Pharmacol., February 1, 2009; 49(2): 176 - 184. [Abstract] [Full Text] [PDF]

				B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, and M. Burnier Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories BMJ, May 17, 2008; 336(7653): 1114 - 1117. [Abstract] [Full Text] [PDF]

				B. Vrijens, E. Tousset, R. Rode, R. Bertz, S. Mayer, and J. Urquhart Successful Projection of the Time Course of Drug Concentration in Plasma During a 1-Year Period From Electronically Compiled Dosing-Time Data Used as Input to Individually Parameterized Pharmacokinetic Models J. Clin. Pharmacol., April 1, 2005; 45(4): 461 - 467. [Abstract] [Full Text] [PDF]